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Hierarchical layered double hydroxide
nanocomposites: structure, synthesis
and applications
Zi Gu,a John James Athertonab and Zhi Ping Xu*a
Layered double hydroxide (LDH)-based nanocomposites, constructed by interacting LDH nanoparticles with
other nanomaterials (e.g. silica nanoparticles and magnetic nanoparticles) or polymeric molecules (e.g. proteins),
are an emerging yet active area in healthcare, environmental remediation, energy conversion and storage.
Combining advantages of each component in the structure and functions, hierarchical LDH-based nano-
composites have shown great potential in biomedicine, water purification, and energy storage and conversion.
This feature article summarises the recent advances in LDH-based nanocomposites, focusing on their synthesis,
structure, and application in drug delivery, bio-imaging, water purification, supercapacitors, and catalysis.
1. Introduction
Recent developments in material chemistry and nanotechnology
have enabled scientists to develop various nanocomposites by
combining different nanomaterials or modifying nanomaterials
with functional molecules. The synthesised nanocomposites
possess appealing and unique properties that render them
attractive for application in healthcare, environmental remedia-
tion, and energy storage and conversion.1–7
Building tailored layered double hydroxide (LDH)-based
nanocomposites is an emerging area in the field of con-
structing 3-dimensional (3D) hierarchical nanoarchitectures
with multiple functionalities. Inorganic LDH compounds,
also known as hydrotalcite-like materials or anionic clays,
can be found naturally as minerals and can also be readily
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synthesised in the laboratory.8 They consist of hydroxide layers
of different metal cations and interlayer spacing occupied
by anions and water molecules.8 At present, LDH nano-
particles can be tailored with the hydrodynamic diameter from
30–40 nm to 5–10 mm using various hydrothermal treatment
methods.9–11 In addition, through various delamination or top
down methods, single-layer LDH nanosheets can be prepared,
with the lateral size from 20 nm to several micrometres.12
Due to their rich ionic surface –OH group and the inherent
positive charge, LDH nanoparticles or nanosheets can interact
with other nanomaterials or polymeric molecules, generating 3D
nanocomposites with particular architectures. We classify LDH-
based nanocomposites into four groups, e.g. core@LDH,
LDH@shell, dot-coated LDH, and targeting moiety function-
alised LDH (Fig. 1). In the core–shell structure, the tailorability
and functionality of LDH endow LDH with a dual role. LDH can
be the shell component that is used to modify other nano-
particles including silica nanoparticles, magnesium ferrite
nanoparticles, etc. (Fig. 1A), and can also be fabricated as the
core coated by other nanomaterials, such as the silica shell or
the polymeric molecule shell (Fig. 1B). The dot-coated LDH is a
new group of composites with smaller silica or metal nano-
particles being deposited on the surface of LDH (Fig. 1C).
Conjugating antibodies, other biopolymers or folic acid on
LDH provides an opportunity for LDH targeting to the site of
disease (Fig. 1D).
With the rapid progress of nanocomposite fabrication,
the research focus has been gradually shifted to practical applica-
tions with the potential of influencing our daily living conditions.
The synthesised nanocomposites often possess the merits and
functions of individual components, thus showing advantages
over the sole nanomaterial.13 There are fewer published appli-
cations on environment and energy; nevertheless, the nano-
composites including silica@LDH,14,15 metal oxide@LDH,16
LDH@metal,17,18 LDH@polymer,19 folic acid–conjugated
LDH,20 etc., have shown promise as drug delivery vectors, water
pollutant removers, high-capacity supercapacitors, and cost-
effective catalysts.
Tailoring the functions of LDH-related nanocomposites is a
relatively new area, yet rapidly evolving area, with a significant
increase in the number of publications over the last 10 years
(approximately 10-fold annual increase from 2004 to 2013;
source from Web of Science). In 2013, Duan and co-workers
published a review focusing on the magnetic nanoparticle@LDH
core–shell nanostructure. Until now no review paper has com-
prehensively summarised the basic strategies to construct 3D
hierarchical LDH-based nanocomposites and their applications
in the fields of biomedicine, environment remediation, and
energy conversion and storage. Thus we believe that it is timely
to review the latest research progress on hierarchical LDH-based
nanocomposites. In this feature article, we summarise the recent
advances in design, fabrication and potential applications of
LDH-based nanocomposites with a highlight on biomedical
applications, and our focus is to link a particular potential
application to the hierarchical structure and building com-
ponents of the corresponding nanocomposites. After a brief
review of LDH nanoparticles and nanosheets in terms of con-
cept, synthesis and applications (Section 2), the LDH-based core–
shell nanoparticles are reviewed as core@LDH (Section 3) and
LDH@shell (Section 4), respectively. The dot-coated LDH nano-
composites and targeting moiety-conjugated LDH nanocompo-
sites for targeted delivery are reviewed in Sections 5 and 6,
respectively. In each section, we examine closely the synthesis
approaches, structures, and key potential applications. In the
final section (Section 7), we provide our perspectives on the
future developments in fabrication and application of LDH-
based nanocomposites.
2. LDH nanoparticles and nanosheets
LDHs consist of brucite-like layers containing hydroxides of metal
divalent and trivalent cations (M2+ and M3+, such as Mg2+, Zn2+,
Fig. 1 Schematic illustration of LDH-based nanocomposites with different
structures: (A) core@LDH (blue: LDH, red: SiO2 nanoparticles, or magnesium
ferrite nanoparticles, etc.), (B) LDH@shell (blue: LDH, red: SiO2 nanoparticles,
protein, polymer, organic hydrophobic modifier, etc.), (C) dot-coated LDH
(blue: LDH, red: metal nanoparticles, SiO2 nanoparticles, etc.), and (D)
targetingmoiety functionalised LDH (blue: LDH, red: folic acid, antibody, etc.).
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Ni2+, Al3+, and Fe3+). Each cation is octahedrally surrounded by six
OH ions, and the different octahedra share edges to form a 2D
layer. Between the brucite-like layers there are exchangeable
anions (Am, such as CO3
2, Cl, and NO3
). The substitution
of M2+ by M3+ in the hydroxide layer results in a positive charge,
which is neutralised by the interlayer anion (Am). The interlayer
space also contains water molecules, hydrogen bonded to layer
OH and/or to the interlayer anions. Due to the electrostatic
interactions and hydrogen bonds, the LDH forms the layered
structure (Fig. 2). The general formula for these LDHs can be
written as [M2+1xM
3+
x (OH)2]
x+(Am)x/mnH2O, where x = 0.2–0.33,
which means the M2+/M3+ molar ratio is 2.0–4.0.8,12,21 The layer
may also consist of monovalent and quadrivalent cations such as
Li+ and Ti4+.8
Various facile synthesis methods have been studied and
used to prepare LDH nanoparticles. Co-precipitation and anion
exchange are the most common ones in the laboratory and
conducted by simultaneously precipitating metal cations at
constant or varied pH. The comprehensive study of LDH
physicochemical properties and synthesis methods has led to
wide applications including drug delivery carriers,22 bio-
sensors,23 water treatment agents,24 catalysts,25 supercapacitors,26
etc. Due to the interlayer anions in the LDH gallery being
exchangeable, various negatively charged therapeutic molecules
and pollutants in wastewaters can be intercalated into the inter-
layer and adsorbed on the LDH surface, which could allow
effective therapy and wastewater treatment, respectively.27–29
LDHs containing transition-metal elements are used as super-
capacitor electrode materials, because the layered structure of
LDHs provides a homogeneous dispersion of transition-metals in
the matrix.30
In recent years, LDH nanosheets are attracting great atten-
tion. Thanks to their 2D anisotropy with around one nanometer
in thickness and tens to thousands of nanometres in lateral
dimension, LDH nanosheets contribute tremendously to funda-
mental research and their application in building functional
nanocomposites.12 In general, LDH single sheets can be synthe-
sised by two approaches, i.e. delamination of LDH nanoparticles
and one-step synthesis of LDH monolayers.12 Delamination of
LDH nanoparticles can be achieved by using a wide variety of
solvents, including butanol, acrylates, formamide, etc.;31–33 and
the one-step synthesis method employs a reverse microemulsion
approach.34,35 The charged nanosheets can be assembled to
produce various nanoconjugates, nanofilms, and nanoarchi-
tectures, which have tremendous potential applications in bio-
medicine, energy storage and energy conversion.36–38
3. Core@LDH nanocomposites
The core@LDH nanocomposites are equipped not only with the
unique physicochemical properties (e.g. nanometre size and
layered structure), but also with new and interesting functions
(e.g. magnetism, porous structure, and high surface-to-volume
ratio). We will summarise the synthesis strategy and morphology
of the core@LDH nanocomposites, and their applications in
drug delivery, water purification, and energy conversion and
storage in this section.
3.1 Synthesis of the LDH shell
Themethod of LDH shell synthesis is generally grouped into three
categories: (1) coprecipitation; (2) the sol–gel method; and (3)
direct deposition (Fig. 3). Coprecipitation is a traditional andmost
commonly usedmethod in the laboratory. The sol–gel method is a
new and interesting approach where AlOOH primer sol serves as
the substrate as well as the aluminium source. Different from the
coprecipitation and the sol–gel method in which LDH grows
in situ on the core, direct deposition is conducted by grafting
pre-synthesised LDHs on the core surface, and especially useful to
fabricate the shell consisting of LDH nanosheets.
3.1.1 Coprecipitation. Coprecipitation is a facile and com-
monly used method for synthesising the LDH shell. The cores
that have been widely studied include silica nanospheres, metal
oxide nanoparticles and nanowires, and the shells produced by
coprecipitation are always LDH nanoparticles. In general, the
core adsorbs two different metal cations that are subsequently
precipitated on the surface of the core, and the LDH crystal
growth occurs by aging at a certain temperature or through
hydrothermal treatment (Fig. 3A). Zhang et al. used the copre-
cipitation method to prepare an anti-inflammatory drug-loaded
LDH shell on the magnesium ferrite core.14,39 In this work,
Fig. 2 Schematic illustration of layered double hydroxide structure and
chemical components.
Fig. 3 Schematic illustration of the fabrication of core@LDH nano-
composites by coprecipitation (A, B), sol–gel (C), and direct deposition (D).
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the magnesium ferrite particle core that first adsorbed Mg2+
and Al3+ cations was mixed with a solution containing sodium
hydroxide and diclofenac or ibuprofen to precipitate.14,39 The
synthesised magnetic drug–LDH nanohybrid possessed a clear
core–shell structure with a diameter around 100 nm.14,39 An
earlier study by Zhang et al. reported a similar core–shell
nanostructure by using the coprecipitation method.40 However,
they failed to produce homogeneous core–shell structured
particles, and the particles had a network-like morphology
where particle aggregation occurred. Following careful exami-
nation of the experiments in these two papers, we reasoned that
ultrasonication might be a critical factor, facilitating metal
cations to be evenly distributed and adsorbed on the surface
of the core material and thus improving homogeneous growth
of LDH. The ultrasound-assisted coprecipitation method
has also been applied to synthesise a variety of core@LDH
nanocomposites, such as SiO2@LDH,
15 Fe3O4@LDH,
16 and
Y2O3:Er
3+,Yb3+@SiO2@LDH.
41
In order to fabricate the homogenous LDH nanostructure on
the surface of a ferrite core, pre-coating the core by a thin layer of
carbon (C–OH) or silica (SiO2) prior to coprecipitation has been
examined (Fig. 3B). A thin layer of carbon coating by the
polymerisation and carbonisation of glucose through a hydro-
thermal reaction generates large amounts of hydrophilic groups
C–OH, which facilitates the formation of the LDH shell on the
ferrite core.42 Silica, due to its surface active –OH group, can
interact effectively with metal oxide nanospheres or LDH nano-
particles to form metal oxide@SiO2@LDH nanocomposites.
36
Taking advantage of this unique property of silica, Chen et al.
coated Y2O3:Er
3+,Yb3+ nanophosphors with a layer of silica and
then precipitated metal cations to form LDH nanoparticles
on the surface of the silica layer, and thus generated a
Y2O3:Er
3+,Yb3+@SiO2@LDH core–shell nanoarchitecture.
41
3.1.2 Sol–gel method. The first sol–gel method to fabricate
LDH shells was reported by Wei and co-workers in 2010.43
In this method, the boehmite (AlOOH) primer sol prepared
by hydrolysing the precursor Al(OPr)3 was deposited on the
scaffold (i.e. paper, cloth or sponge) with several cycles of
sol–gel deposition (Fig. 3C).43 The generated AlOOH coating
as both substrate and source of aluminium resulted in
LDH in situ growth on the scaffold (Fig. 3C).43 Using this
method, Shao et al. successfully synthesised SiO2@LDH and
Fe3O4@SiO2@LDH core–shell composites with diameters of
B600 nm and B900 nm, respectively.44,45 Based on the
SiO2@LDH core–shell structure and the sol–gel method, the
same group also synthesised a SiO2@LDH yolk–shell and
hollow structure by adjusting the concentration of urea.44
Using the sol–gel method, Wang et al. coated a much smaller
SiO2 core (50 nm, compared with Wei et al.’s 340 nm) with LDH
and generated SiO2@LDH core–shell nanocomposites.
46 The
sol–gel method can also be applied to grow LDH on the carbon-
coated Fe3O4, but failed to produce well-dispersed, homo-
genous core–shell particles.47
3.1.3 Direct deposition. In the direct deposition approach,
the core material and LDH nanoparticles or nanosheets are
synthesised separately, and subsequent combination of these
building blocks generates a core–shell structure by self-
assembling, followed by some post-treatment (Fig. 3D).
Ay et al. and Li et al. used the direct deposition method to
synthesise magnetic metal oxide core@LDH shell nanocompo-
sites by adsorbing LDH nanoparticles on the core surface.48,49
Li et al. also investigated the effect of post-aging temperature
on the structure and physicochemical properties of the core–
shell nanocomposites. With the temperature increasing from
100 to 160 1C, the LDH particles increased in size and crystal-
linity, and the morphology of LDH changed from flocculent-
like to platelet-like shape.49 Very interestingly, Choy and
co-workers formulated bio core@inorganic shell nanohybrids
with a size of around 100 nm by mixing designed DNA solution
(negatively charged) and a solution containing LDH nanosheets
(positively charged) together.50 The transmission electron
microscopy image of this nanocomposite showed a clear core
(biomolecule, e.g. DNA)–shell (LDH) structure with the shell of
B10 nm thickness. Nonetheless, accurate control of deposited
LDH density remains a challenge.
Coating LDH nanosheets on the core sphere via layer-by-layer
deposition produces a multi-layered LDH shell in a controlled
manner. Sasaki’s group fabricated a polystyrene bead@LDH
nanosheet core–shell microsphere by depositing 20 layers of
poly(sodium 4-styrene sulfonate)–LDH nanosheets.51,52 The core
was later on used as a sacrificial template in this work. Based on
this technique, Li et al. synthesised functional Fe3O4–SiO2 core
coated with 20 layers of alternating carbonate and LDH
nanosheets ((CO3
2/LDH)20).
53
Electrodeposition is a widely applied coating technique in
industry to graft one material on the other, and this is also useful
to assemble LDH nanoparticles or nanosheets on nanowires.54
Using this method, LDHs with positive charges are suspended in
water and migrate towards the electrode scaffold (i.e. nanowire)
under the influence of electrophoresis to construct a 3D hierar-
chical metal oxide nanowire@LDH nanoarchitecture.54
3.2 Morphology of core@LDH nanoparticles
In general, the LDH shell in the core–shell nanoarchitectures
possesses three different but interactive morphologies, i.e.
horizontally oriented platelets, vertically oriented platelets,
and mixed platelets (Fig. 4). The horizontally oriented platelet
morphology tends to be formed by direct deposition of LDH
nanosheets on the core materials (described in Section 3.1.3)
and possibly by coprecipitation (described in Section 3.1.1).50,53
The LDH nanosheets have a high aspect ratio, large surface
area, and desirable flexibility to be curved, which facilitate the
nanosheets to adhere horizontally onto the sphere core. The
vertically oriented platelet morphology is an interesting one
that creates a porous structure, thus favoured by the researchers
in the area of drug delivery and water purification. The LDH
shell oriented vertically on the core is often generated by the
sol–gel method (described in Section 3.1.2) and sometimes by
coprecipitation.41,44,45,55 The coexistence of horizontally and
vertically oriented platelets leads to the formation of the third
morphology, i.e.mixed platelets. The mixed platelet morphology
was firstly denoted by Zhang et al. who fabricated magnetic
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core@LDH shell nanocomposites using the coprecipitation
method.14 This type of morphology has been seen in most cases
of coprecipitation and direct deposition,42,55 and sometimes in
the sol–gel method.46
The linkage between the LDH shell and the metal oxide core
has been proposed as MI–O–MII bonds where MI and MII
represent metal cations from LDH and the core, respec-
tively.40,56 There are two possible interactions between the core
and the shell via MI–O–MII bonds: (1) MI–O–MII bonds
perpendicular to the LDH layer generate the horizontally
oriented LDH shell, and (2) MI–O–MII bonds parallel to the
LDH layer form the vertically oriented LDH shell.40 Zhang et al.
suggested that the vertically oriented LDH morphology is more
easily formed because of the more unsaturated sites localised
near the edge of LDH layers.40 However, they did not give
explanation for the formation of the horizontally oriented
LDH shell. More recently, Chen et al. synthesised Fe3O4@LDH
core–shell nanocomposites with different morphologies by
adjusting the methanol/water solvent ratio.55 They found that
the vertically orientated morphology was formed in the water
(no methanol) environment, and the mixed morphology
formed in the solvent containing methanol and water (volume
ratio 1 : 1).55 In their proposed mechanism, the formation of the
former structure, i.e. the vertically oriented LDH, is due to the
rapid nucleation of LDH compactly packed on the core surface,
simultaneously upon the LDH crystal growth on the (110) plane
faster than on the (003) plane.55 Unfortunately, they did not
illustrate the formation mechanism of the mixed morphology.
Here, we tentatively propose an assumption to explain the
mechanism of different LDH shell morphologies formed by
coprecipitation based on the formation mechanism of the
vertically oriented LDH on Fe3O4 nanoparticle cores proposed
by Chen et al.55 When nucleation is fast, e.g. high supersaturation,
the LDH nuclei are compactly packed on the core surface. Because
of the limited growth space, the horizontally oriented nuclei
initially formed are sacrificed and subsequently contribute to the
crystal growth of the vertically oriented LDHs. Eventually, the
vertically oriented LDH shell morphology becomes dominant with
the growth along (110) more readily accessible than that along
(003) (Fig. 5A). On the other hand, when the nucleation rate is
severely restricted by some factors such as the low supersaturation
or solvent, the LDH nuclei are sparsely attached on the core. As the
LDH nuclei grow, the relatively smaller vertically oriented LDHs
(due to the restriction of growth by the core) are sacrificed, and
thus the relatively larger horizontally oriented LDH crystals
become dominant (Fig. 5B). In the situation between these two
cases, the mixed platelet morphology forms (Fig. 5C). To the best of
ourknowledge,noone reports thehorizontally orientedmorphology
of theLDHshell formedby coprecipitation,whilewe still suggest the
possibility to tailor the morphology of the nanocomposites by
properly controlling the nucleation rate based on our assumption.
Therefore, synthesis conditions that influence the nucleation rate
need to be carefully examined in order to design and fabricate LDH-
coated nanocomposites with a specific morphology.
3.3 Applications of core@LDH nanocomposites
Owing to their unique properties such as high surface area,
magnetism and porous structure, the core@LDH nanocompo-
sites have been examined for their application in drug delivery,
water purification, and energy conversion and storage.
3.3.1 Drug delivery. Drug delivery, as one of the most
important applications of functional core@LDH nanocompo-
sites, allows ideally sustained, controlled, and/or targeted
delivery of therapeutic compounds with the aim of improving
their therapeutic effects. The core provides a matrix for the
shell growth, and more importantly endows the nanocomposite
with extra functional properties, such as ferric magnetism and
superparamagnetism. The LDH shell serves as an efficient drug
host by intercalating/releasing the drug/gene anions into/from
the LDH interlayer,27,57,58 as the interlayer anions of LDHs can
be exchanged with other anions in the medium with the affinity
order of CO3
2 4 HPO4
 4 CrO4
 4 SO4
2 4 OH 4 F 4
Cl 4 Br 4 NO3
4 I.8 Drug/gene anions are released from
Fig. 4 Schematic illustration and SEM images of core@LDH nanoarchi-
tectures with different morphologies: horizontally oriented platelets (A, A0),
vertically oriented platelets (B, B0), and mixed platelets (C, C0). Images
A0–C0 are reproduced from ref. 53 and 55 with permission.
Fig. 5 Schematic illustration of formation of core@LDH nanocomposites
with (A) vertically oriented, (B) horizontally oriented, and (C) mixed platelet
morphology.
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the LDH shell by diffusing from the LDH interlayer and/or by
LDH layer dissolution, and the drug/gene release from the
composites always shows a sustained release profile, in which
an initial burst release can quickly establish the therapeutic
dose and the subsequent prolonged release maintains this dose
for a long period of time.
The drugs intercalated in the LDH shell include anti-
inflammatory drugs (e.g. diclofenac, ibuprofen, and glucuronic
acid),14,56,58 anti-cancer drugs (e.g. doxorubicin, doxifluridine,
and 5-fluorouracil),41,42,49 and hepatitis B virus DNA vaccine.46
Wang et al. synthesised SiO2@LDH nanocomposites with an
average diameter of 210 nm and mixed platelet morphology.46
They claimed that the most important advantage of this nano-
composite over other nanomaterials was its larger surface area,
which could allow the loading and delivery of a large amount
of DNA vaccine.46 They also found that DNA vaccine loaded-
SiO2@LDH immunised mice demonstrated much higher serum
antibody response than naked DNA vaccine, and enhanced T-cell
proliferation and skewed T helper to Th1 polarisation.46 In the
physiological environment, the loaded drugs are released in a
sustained manner from the nanocomposites by anion exchange
and/or nanocomposite biodegradation.27
Zhang et al. designed a controlled drug release device by
coprecipitating the mixed platelet LDH shell with diclofenac
loading on the magnesium ferrite nanoparticle core (Fig. 6A).14
Under an external magnetic field, they observed a decreased
drug release rate (B20% decrease) in pH 7.45 phosphate buffer
saline (PBS), which is presumably resulted from the aggregation
of the magnetic nanocomposites triggered by magnetic force
(Fig. 6B and C).14,39 This group also claimed that the overall
release profile was determined by three diffusion paths of the
loaded drug from the magnetic nanohybrids (Fig. 6D): (I) intra-
particle diffusion from the LDH interlayer space to the LDH
interparticle space, (II) interparticle diffusion from the space
among the LDH particles to the inter-aggregate space, and (III)
inter-aggregate diffusion from the space among the core–shell
particle aggregation to solution.14 When the magnetic field was
applied, the magnetic core–shell nanohybrids aggregated, leading
to longer diffusion length, higher diffusion resistance, and a
decreased drug release rate (Path III) (Fig. 6B and D).14,39 Apart
from the controlled release, targeted delivery of drugs to the
diseased site using the magnetic core–shell nanohybrids is also
promising with the application of an external magnetic field.58 The
magnetic drug delivery system concentrates the drug dosage at a
target site with the aid of an external magnetic field, thus avoids
nonspecific drug delivery, enhances the therapeutic effect and
reduces the drug side effects.59,60 The targeted delivery can also be
achieved by conjugating antibody and other ligands on the LDH
nanoparticles,49,61 and will be described in detail in Section 6.
3.3.2 Water purification. Pollutants in waste waters or
aquatic systems have become an emerging environmental
and health issue.62,63 In recent years, adsorption by LDH-
consisted core–shell nanoarchitecture via ion exchange is
recognised as an efficient and low-cost approach to remove
pollutants (i.e. acidic pharmaceutical compounds, fluoride, and
heavy metal) from waste waters.15,16,47
Chen et al. reported a typical vertically oriented SiO2@LDH
core–shell nanocomposite synthesised by ultrasound-assisted
coprecipitation (Fig. 7A), which showed much more efficient
Fig. 6 (A) TEM image of diclofenac-loaded magnesium ferrite nano-
hybrids (DIC-M) with the mixed platelet LDH shell. The inset shows the
schematic illustration of DIC-M core@shell morphology with the mixed
platelet shell. (B) Release curves of DIC from DIC-M, DIC-LDH and the
DIC-loaded physical mixture of magnetic nanoparticles and LDH (DIC-Mix)
in pH 7.45 PBS. The inset shows the release curves of DIC-M with and
without an external magnetic field. (C) SEM images and schematic illustra-
tion of the magnetic nanoparticle@LDH nanohybrid: (a, d) without an
external magnetic field, (b, e) with an external magnetic field, and (c, f)
when removing the magnetic field. (D) Three diffusion paths of the loaded
drugs from the magnetic nanoparticle@LDH nanohybrid: (I) intraparticle
diffusion from the LDH gallery space, (II) interparticle diffusion from the
space among the LDH particles, and (III) interparticle diffusion from the
space among particle aggregates to solution. Modified and reproduced
from ref. 14 and 39 with permission.
Fig. 7 (A) SEM images of SiO2@LDH nanocomposites. The inset shows
the schematic illustration of their vertically oriented platelet core–shell
morphology. (B) Kinetic study (a) and the adsorption isotherm (b) of
diclofenac on (i) SiO2@LDH and (ii) LDH. (C) Percentage of diclofenac
removal using SiO2@LDH in cycle runs. Modified and reproduced from
ref. 15 with permission from The Royal Society of Chemistry.
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adsorption of diclofenac (a typical pharmaceutical pollutant)
than LDH aggregates in terms of the adsorption rate and
capacity (Fig. 7B).15 They found that the higher adsorption
capacity of diclofenac on this core–shell nanocomposite
(758 mg g1) than that on LDH aggregates (489 mg g1) was
mainly related to the large surface area of the vertically oriented
LDH shell (Fig. 7B).15,64 The adsorption capacity of diclofenac
by SiO2@LDH (758 mg g
1) is also obviously higher than that by
polymers (324.8 mg g1)64 and mesoporous silica (0.34 mg g1).65
Themagnetic nanoparticle@LDH core–shell nanocomposites have
also been synthesised to remove fluoride ions and uranium(VI)
from aqueous solutions.16,47
After pollutant adsorption, regeneration and re-utilisation of
the spent adsorbents is a vital process in large-scale cost-
effective wastewater treatment. The feasible and efficient
approaches to regenerating core@LDH nanohybrid adsorbents
include (1) advanced oxidation to decompose the adsorbed
compounds and (2) desorption of the pollutant in the eluent
to re-use.15,16,47,66 With advanced oxidation, Chen et al.
reported the removal efficiency of SiO2@LDH being consis-
tently above 90% for at least four runs by using Co2+ ions and
ozone as the catalyst and oxidant, respectively (Fig. 7C).15 The
desorption efficiency is dependent on the affinity of inter-
calated anions in the LDH-based adsorbent and the anions in
the eluent. In general, the eluent containing CO3
2 had the
highest desorption efficiency of around 80%.16,47
3.3.3 Energy conversion and storage. Many efforts have been
made to develop efficient and sustainable energy storage and
conversion approaches because of ever worsening energy depletion
and global warming.67–69 The core@LDH nanocomposites with
enhanced supercapacitor and catalyst behaviour can be poten-
tially applied in energy storage and conversion devices.56
The characteristic properties of a supercapacitor candidate
include high redox activity, high surface area, and suitable
mesopore/micropore size distribution. Researchers have found
that the synthesised 3D hierarchical core@LDH architectures
possess these properties, and show excellent supercapacitive
performance in terms of capacitance, energy density, and the
cycling rate.44,54,70 With different synthesis methods applied
(such as deposition and sol–gel), these core@LDH architectures
always have vertically orientated or mixed platelet morphology
which allows the nanocomposite to form porous structure and
enlarge the surface area to the maximum extent.44,54,70 The
different interior hierarchy structures (SiO2@LDH core–shell,
yolk–shell, and hollow LDH shell) have also been compared in
their supercapacitive performance. Shao et al. showed that the
hollow NiAl–LDH structure had greatly improved faradaic redox
reaction and mass transfer, and exhibited excellent pseudo-
capacitance performance because of the large surface area of the
hollow structure, which provides effective diffusion channels for
the electrolyte ions.44 Wang et al. synthesised a hierarchical
NiAl–LDH@mutiwalled carbon nanotube nanocomposite that
grew on nickel foam with an exceptional areal capacitance
(7.5 F cm2) and specific capacitance (1293 F g1).71 These
values are among the highest that are reported so far for other
oxide/hydroxide derived architectures, such as NiTi–LDH/NF
film (10.37 F cm2),72 b-Ni(OH)2/NF (2675 F g
1),73 hierarchical
Ni0.25Co0.75(OH)2 (928.4 F g
1 or 9.59 F cm2),74 hybrid nickel
hydroxide/carbon nanotube (16 F cm2),75 and 3D nanostructure
CoO@Ni(OH)2 (11.49 F cm
2).76 This new hierarchical structure
shows as a highly promising electrode that can be applied in
electrochemical energy storage.71
In addition to supercapacitors, core@LDH has been studied
as a catalyst to convert acetone to diacetone alcohol as an
alternative fuel component at the thermodynamic equilibrium
with the conversion of 23% at 273 K.56 The authors claimed
that the catalyst was easily recovered attributed to the magnetic
core and reactivity in the second run remained unchanged.56
3.3.4 Other applications. Other applications of the core@LDH
nanocomposites include immunosensors,61 a DNA-based document
ID system,50 and purification of recombinant proteins.45 Fewer
studies in these interesting areas may imply that more efforts
should be directed into these applications.
4. LDH@shell nanocomposites
Continuous efforts have been dedicated to producing the shell of
different matters on the LDH core for application in healthcare,
energy conversion and storage. The functionalisation methods,
including adsorption, polymerisation, etc., take advantages of
LDH surface –OH groups and its surface positive charge. Thanks
to the successful innovation of these methods, a variety of
functional nanomaterials (i.e. silica nanoparticles, polymers, and
proteins) and small molecules (i.e. surfactant and folic acid) have
been anchored on the LDH core to form various LDH@shell
nanocomposites. This kind of combination can be regarded as the
surface modification of LDH nanoparticles to improve LDHs’
functionality, and also viewed as combining the advantages and
functions of the LDHs and the functional nanomaterials for their
practical applications, such as drug delivery, imaging, catalysis,
and energy storage, as summarised in this section.
4.1 LDH@SiO2
To encapsulate LDH with SiO2 to form LDH@SiO2 nanorattles,
tetraethyl orthosilicate Si(OC2H5)4 (TEOS) is used as the source
of silica, and hydrolysed on the surface of the LDH core (as a
nuclear). The linkage between these two inorganic nanomater-
ials (LDH and SiO2) is suggested to be –M–O–Si– (M is the metal
cation in the brucite-like layer of LDH), as illustrated in Fig. 8.
Fig. 8 Schematic illustration of the interaction between LDH and SiO2 in
the LDH@SiO2 nanostructure. M represents metal cations (e.g. Mg
2+, Al3+).
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In 2011, Zhao’s group synthesised a novel uniform core–
shell nanostructure with LDH as the core and ordered meso-
porous silica as the shell.77 The morphology of this core–shell
nanocomposite observed under TEM is interesting, showing
two types of nanostructures (Fig. 9A): (1) mesoporous nano-
plates, and (2) rod-like cores covered by ordered mesoporous
silica.77 These two nanostructures are suggested to be projec-
tions of LDH@SiO2 nanocomposites from two perpendicular
directions (Fig. 9A).77 By adjusting the amount of TEOS, the
average thickness of the mesoporous silica shell could be tuned
between 20 and 50 nm.77 The LDH@SiO2 nanocomposites
retain the properties of both LDH and SiO2, including high
drug loading capacity, dispersivity and biocompatibility,
sustained release of anionic drugs, and ready surface modifica-
tion.77 Meanwhile, Liu et al. synthesised a LDH@SiO2 nano-
structure for drug delivery (Fig. 9B).78 Although the particles
were less controllable in morphology compared with Zhao
group’s work, they still showed sustained release of the drug
and other important properties for drug delivery.78
Apart from being a drug carrier,79,80 the LDH@SiO2 nano-
composite has been investigated as a catalyst precursor.81
Shi’s group fabricated a multi-nanoparticle-embedded core@
mesoporous silica shell structure.81 The core consisted of
aluminium/magnesium oxides (that were then converted to
LDH) and Au nanoparticles, in which the aluminium/
magnesium oxides provided an essential support for Au nano-
particles, and the mesoporous silica shell offered the diffusion
channels for reactants and products, allowing efficient access
of reactants to the catalytic nanoparticles inside.81
4.2 LDH@protein
Protein is an amphiphilic biopolymer, and its interactions
with LDH nanoparticles provide a new way to stabilise the
colloidal stability, and moreover, to deliver protein/peptide-
based drugs. There are a few investigations on the interactions
between LDH nanoparticles and various proteins. An et al.
assembled protein-adsorbed LDH nanosheets in HCl-Tris buffer,
and studied the conformations and orientations of three
adsorbed proteins (porcine pancreatic lipase (PPL), haemoglobin
(Hb), and bovine serum albumin (BSA)) (Fig. 10).82 The structure
and conformations of PPL were well retained because of negative
charges concentrated on the side opposite to the active centres,
and the orientations of PPL could be lying flat or standing
up depending on the ratio of PPL and LDH (Fig. 10a). The
bioactivity of PPL was thus enhanced in the hydrolysis and
kinetic resolution in comparison with its soluble counterpart.
The secondary structure and redox-active heme groups of Hb
were not denatured either, but its tertiary or quaternary structure
was changed through unfolding (Fig. 10b). The negative charges
on the BSA surface were distributed along the linearly arranged
domain I and II, resulting in the unfolded secondary structure
(Fig. 10c). Therefore, the conformation and orientation of
proteins on LDH nanosheets are dependent on the charge distri-
bution and structural features of the proteins. These authors
further suggested that the LDH nanosheet could improve the
activity and stereoselectivity of at least some lipases.82
Kong et al. reported the assembled LDH nanosheets with Hb
and horseradish peroxidase via the layer by layer deposition
technique. They found that the assembled protein/LDH
electrode showed remarkable electrocatalytic activity towards
oxidation of catechol in a wide linear response range, a low
detection limit, high stability and reproducibility.83 Bellezza
et al. observed that proteins (myoglobin and BSA) strongly
interacted with NiAl–LDH or NiCr–LDH nanoparticles and
exhibited a Langmuir-type adsorption.84,85
Our group also constructed the LDH nanocomposites with
ovalbumin (OVA) (Fig. 11A) and BSA coating to modulate immune
response and improve LDH stability, respectively.86,87 The adsorp-
tion of OVA and BSA on LDH nanoparticles was well fitted with
the Langmuir model (Fig. 11B and C); the maximum monolayer
adsorption capacity was 0.58 mg mg1 for OVA (Fig. 11B),86 and
0.70 mg mg1 for BSA (Fig. 11C) on 110 nm LDH nanoparticles.87
Coating OVA on LDH demonstrated that LDH as an adjuvant
induced a high level of IgG1 antibodies comparable to Alum
(an FDA approved adjuvant for human vaccination) but with
much weaker inflammation.86 BSA pre-coating prevented LDH
Fig. 9 TEM images of LDH@SiO2 nanocomposites. The upper images of
(A) show the TEM images of one LDH@SiO2 nanocomposite observed at
different angles by tilting the specimen with a step of 10 degree and the
bottom pictures of (A) are the corresponding cartoon profile, where the
typical nano-rods and nanoplates are shown in (B) and (C). Reproduced
from ref. 77 with permission from The Royal Society of Chemistry.
Fig. 10 Top images show electrostatic surface potentials for (a) porcine
pancreatic lipase, (b) haemoglobin, (c) bovine serum albumin at pH 7.4.
Bottom pictures schematically illustrate possible orientations of (a) porcine
pancreatic lipase, (b) haemoglobin, (c) bovine serum albumin on the posi-
tively charged 2D LDH surface. Reproduced from ref. 82 with permission.
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and drug/gene-loaded LDH from aggregation in the electrolyte
solution (physiological environment) and enhanced the cellular
uptake, possibly due to the improved colloidal stability of nano-
particles in the culture medium solution.87
4.3 LDH@polymer
There are two main methods to functionalise LDH nano-
particles with polymers: (1) adsorption of pre-synthesised
polymers via electrostatic interaction,19,88–90 (2) in situ poly-
merisation, including one-pot in situ polymerisation,91 surface-
initiated atom transfer radical polymerisation (ATPR),92,93 and
crosslinking.94 Adsorption of anionic polymers on the LDH
surface can be achieved by simply mixing the two components
or via electrodeposition. This synthesis method takes advan-
tages of the positive charge on the LDH surface, thus the
conjugated polymers are required to be negatively charged.
Because of its facile procedure, adsorption is the most common
method used to synthesise LDH@polymer nanocomposites.
One-pot in situ polymerisation uses LDH nanoparticles as the
template/core to polymerise the anionic monomers, without
washing and transferring steps. In this method, the monomer
is often anchored on the LDH core via electrostatic attraction.
The surface-initiated ATPR originates from the atom transfer
step, which allows uniform growth of the polymeric chains.95
Moreover, the ATPR reaction can be achieved under environ-
mentally friendly conditions using water as the solvent.96
Cross-linking is usually achieved by covalently cross-linking
polymers that are adsorbed on the LDH surface via a cross-
linked agent (e.g. glutaraldehyde).94
The main application of LDH@polymer nanocomposites is
drug/gene delivery. Hu et al. tailored the functionality of LDH
surfaces through surface-initiated ATPR of 2-(dimethylamino)-
ethyl methacrylates.93 This LDH composite with the flexible
polycation brushes (2-(dimethylamino)-ethyl methacrylates)
demonstrated increased ability to condense plasmid DNA,
and higher cellular uptake and gene transfection efficiency in
COS7 and HepG2 cell lines.93 Poly(ethylene glycol) (PEG) is
considered a biocompatible polymer, and widely used to func-
tionalise other drug delivery carriers with the aim of increasing
colloidal stability and circulation time.97–99 For example,
Li et al. synthesised anionic PEG functionalised LDH nano-
hybrids.90 This LDH@PEG nanohybrid displayed enhanced
colloidal stability and re-dispersing ability compared with LDH
itself, due to the polymer steric hindrance and the electrostatic
repulsion.90 Colonic delivery is the other important area of
LDH@polymer application. In order to improve the muco-
adhesive ability and controlled release in acidic environments,
the drug carrier LDH is coated with Eudragit or pectin to enhance
the structural integrity in the acidic environment.88,100–103
The LDH@polymer is also applied for high-performance
energy storage. Han et al. fabricated a LDH@poly(3,4-
ethylenedioxythiophene) (PEDOT) core–shell nanoplatelet array
(NPA) grown on a flexible Ni foil substrate as a high perfor-
mance pseudocapacitor (Fig. 12A), in which the LDH core
provided high energy storage capacity, and the polymer shell
and its porous structure facilitated electron/mass transport in
the redox reaction.19 The LDH@PEDOT core–shell NPA showed
a maximum specific capacitance of 649 F g1 by cyclic voltam-
metry (scan rate was 2 mV s1) and 672 F g1 by galvanostatic
discharge (current density was 1 A g1) (Fig. 12B and C).19 The
specific capacitance of the well-arranged LDH@PEDOT NPA
(672 F g1) was much higher than its counterpart LDH@
PEDOT–Ni foam (334 F g1), indicating that the mesoporous
and well-ordered structure enhances ion diffusion of the
electrolyte and electron transfer.19
Fig. 11 (A) Schematic illustration of the Mg2Al–LDH-based adjuvant–
antigen hybrid system with OVA surface-adsorbed and CpG surface-
adsorbed or intercalated. (B, C) OVA or BSA adsorption isotherm over
Mg2Al–LDH nanoparticles, and data are expressed as mean  SD and mean
 SEM respectively. Reproduced from ref. 86 and 87 with permission.
Fig. 12 (A) Schematic illustration of fabricating LDH@PEDOT core–shell
nanoplatelet array (NPA) electrode. (B) Cyclic voltammetry curves of the
LDH NPA, PEDOT, LDH@PEDOT NPA and bare Ni foil electrode measured
at a scan rate of 2 mV s1. (C) Specific capacitance of the LDH@PEDOT NPA
electrode as a function of deposition time. (D, E) Specific capacitance of
pristine LDH NPA and LDH@PEDOT NPA electrodes, respectively, at various
discharge current densities. Reproduced from ref. 19 with permission.
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4.4 LDH@organic hydrophobic modifier
Different from polymers, the organic modifiers with much smaller
molecular weight are anchored on the LDH surface with the aim of
modifying LDH’s intrinsic hydrophilic properties.
The organic modifiers include various surfactants (such as
sodium dodecyl sulphate, dodecylsulfonate, and dodecylbenzene-
sulfonate) and other anionic organic molecules (hexanoic acid
and silane coupling agents).89,104–108 Hydrophobicmodification of
LDH is applied in drug delivery of hydrophobic pesticides and
dyes,106,107 as well as in biofuel production.105,108 It is worth
noting that some of the organic modifiers are not only anchored
on the surface of the LDHmatrix, but also intercalated in the LDH
gallery space, and the ionic affinity of the molecules may allow
partial exchange of anions between LDH layers.
5. Dot-coated LDH nanocomposites
Recently, dot-coated LDH nanocomposites as a group of
new hierarchical hybrid materials have attracted interest. The
dot-coated LDH consists of an LDH substrate and other smaller
sphere-shaped nanodots coated on the surface of LDH (Fig. 1C).
Different from the LDH@shell nanocomposites, the surface of
LDH is only partly covered by coated dots, thus presenting
a new hierarchical structure of LDH nanocomposites and
exhibiting some exciting advantages, such as the possibility of
multi-functionalising LDH. Moreover, the increased particle
surface roughness could also enhance cell binding and subse-
quent engulfment by cells in biomedical applications.109 The
coating nanomaterials that have been developed include metal
nanoparticles (e.g. Au nanoparticles, Pd nanoparticles, and Ag
nanoparticles) and SiO2 nanoparticles,
17,18,110,111 and the
synthesised dot-coated LDHs have been examined in drug
delivery and simultaneous bio-imaging, and catalysis.
5.1 Metal nanoparticle dot-coated LDH
Shi’s group reported Gd-doped LDH@Au nanocomposites to
dually function as a drug carrier and a diagnostic agent.18 As
claimed by the authors, the advantage of this nanocomposite over
other nano-systems is that the imaging agents (i.e. Gd3+ and Au
nanoparticles) can be easily and effectively introduced into LDH
and thus form the unique dot-coated nanocomposite structure. In
this structure, Gd3+ as the magnetic resonance imaging contrast
agent was doped in the LDH lattice via the coprecipitation
method, and Au nanoparticles with an average diameter of
3.4 nm were incorporated in the nanocomposite by depositing
Au(OH)3 on the surface of LDH under alkaline conditions,
followed by the reduction with NaBH4 (Fig. 13A and B).
18 This
LDH–Gd@Au nanocomposite had an average hydrodynamic
diameter of around 140 nm, and was well-dispersed in water
(Fig. 13C).18 By culturing mouse fibroblastic cell lines and human
cervical cancer cell lines in vitro, the authors showed enhanced
doxorubicin delivery efficiency with LDH–Gd@Au compared with
free doxorubicin (Fig. 13D).18 Meanwhile, thanks to the compo-
nent of Gd3+ and Au, the LDH–Gd@Au nanocomposite acted
efficiently as a dual-functional contrast agent for magnetic
resonance imaging and X-ray computed tomography imaging
in a tumour-bearing mice model (Fig. 13E).18
Zhao et al. anchored finely dispersed Pd nanodots
(B1.8 nm) to CoAl–LDH nanoparticles (B1.5 mm) via a facile
in situ redox reaction between the Co2+ in LDH nanoparticles
and the PdCl4
2 precursor.17 This architecture showed
enhanced catalytic activity and robust durability towards
ethanol electro-oxidation compared with the commercial Pd/C
catalyst, in which LDH played a ternary role: a catalyst support,
a stabiliser of Pd nanodots, and a reducing agent (without any
external agent).17 Zhao et al. claimed that this work provided
a promising approach to fabricating highly efficient nano-
catalysts that could be used in fuel cells and other related
catalytic reactions.17
Apart from these two examples in biomedical and catalytic
applications, metal nanoparticles, such as Ag nanoparticles
and quantum dots, have also been dot-coated onto the surface
of LDH and investigated in the field of sterilisation and light
emitting diodes.110,112,113
5.2 SiO2 nanoparticle dot-coated LDH
Our group recently synthesised amine-functionalised SiO2 dot-
coated LDH (LDH@SiO2–NH2) nanocomposites via electrostatic
interactions and condensation of APTES (Fig. 14a).111 This
synthesis strategy is different from the one for LDH@SiO2
discussed in Section 4.1, with the purpose of fabricating the
dot-coated nanostructure instead of the core–shell structure.
SiO2 nanodots (Z-average size of 10–15 nm, zeta potential of
Fig. 13 (A) Schematic illustration, (B) SEM images, and (C) dynamic light
scattering size distribution of LDH–Gd@Au nanocomposites. (D) HeLa cell
viabilities when exposed to free doxorubicin and LDH–Gd@Au–doxorubicin
at concentrations of 0–25 mg ml1 (*p o 0.05, **p o 0.01, ***p o 0.001).
(E) X-ray CT (upper images) and MRI (bottom images) imaging of tumour
after intravenous injection of LDH–Gd@Au–heparin in 4T1 murine breast
tumour-bearing mice for 0, 1, 4 h. Modified and reproduced from ref. 18
with permission.
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38.8 mV) and LDH nanoparticles (approximately 110 nm,
+42.5 mV) were synthesised separately, and then mixed to form
LDH@SiO2 nanocomposites via electrostatic attraction.
111 The
nanocomposites were modified with –NH2 by condensing
APTES on the surface.111
The resulted LDH@SiO2–NH2 had the average hydro-
dynamic diameter of 256 nm, and showed uniform SiO2
nanodots of around 10–15 nm attached on the surface of
LDH (Fig. 14b–g).111 The amine-functionalised SiO2 dot-
coating improved LDH dispersion in the culture medium and
PBS, and more importantly enhanced siRNA delivery to the
U2OS cell line to inhibit cell proliferation, probably due to the
improved nanoparticle dispersion.111 We also suggest that
the enhanced endosomal escape increases cell death,111 in
comparison with the positively charged silica nanoparticles,114
which seems to be less capable for the proton sponge effect.
6. LDH@targeting moiety
There are numerous barriers for nanoparticle-based drug
carriers en route to their target, such as mucosal barriers and
non-specific uptake.115–117 Thus it is necessary to combine the
rational design of nanocarriers with moieties to encourage
active targeting. This may also allow a more favourable
benefit-risk profile by reducing organ toxicity, which often
limits the clinical effectiveness of anthracyclines. Indeed, as
tumour-free survival improves with novel chemotherapeutics,
their impact of overall survival is often limited by organ toxicity,
which could be potentially mitigated by nanocomposite-based
drug delivery.118 In the case of LDH nanocarriers, recent progress
in targeting moiety design has been seen in conjugating folic acid
and antibody agents.20,57,119–121
Folic acid has a high affinity (Kd E 100 pM) for folate
receptors which are often overexpressed in various human
cancers, such as ovary, lung, kidney, colon cancer, etc.122–125
By conjugating this cancer cell specific ligand on LDHs, Choy’s
group described the selectivity of this nanohybrid to folate
receptor-overexpressed cell lines (i.e. human nasopharyngeal
epidermoid carcinoma cells) in comparison with folate receptor
deficient cell lines (i.e. human lung adenocarcinoma epithelial
cells).20 It is worth noting that the anionic type of folic acid can
be intercalated into the LDH gallery space, which may result in
the targeting function of folic acid being shielded.126–128 To
address this issue, the researchers from the same group grafted
folic acid on the surface of LDH by covalent coupling using
silane coupling reagents APTES and 1-ethyl-3-(3-dimethyl-
aminopropyl)-carbodiimide (EDC).20 To do this, the surface of
LDH nanoparticles was modified with APTES, whose amine end
group could be conjugated with the functional groups such as
carboxylate and thiocyanate.20 For example, the activated
carboxyl group of folic acid by N-hydroxysuccinimide, using
EDC as a coupling agent, was then combined with the amine
end group of APTES on the surface of LDH to form LDH@folic
acid composites.20
To target vascular injury caused by surgical treatment (e.g.
angioplasty), our group conjugated anti-coagulant drug low
molecular weight heparin (LMWH)-intercalated LDH nano-
particles with a cross-linked fibrin antibody (an antibody that
rapidly accumulates at the site of vascular injury and remains
for many weeks) by associating the sulfhydryl-modified anti-
body with the maleimide-containing LMWH.121,129–131 With
this LMWH–LDH@antibody, we observed specific delivery of
drugs to the site of injury, reduced luminal loss and thrombotic
occlusion in a rat model of arterial injury.121
7. Conclusions and perspective
This feature article summarises the recent progress in synthesis
approaches, physicochemical properties, and potential applica-
tions of LDH-based nanocomposites. The hierarchical LDH
nanocomposites, combining the advantages of LDH nano-
particles/nanosheets and other nanomaterials/molecules, do
not only show the advantages over each component of the
nanocomposites, but also show some superiority to other
nanomaterials such as polymers, metal oxide and mesoporous
silica nanoparticles, when they are applied in drug delivery,
imaging, water purification, catalysis, and energy storage. Some
exciting research contributions are highlighted in this feature
article to illustrate the unique structures, excellent properties,
and important applications of the hierarchical LDH nano-
composites. In particular, the synthesis and application of
dot-coated LDH nanocomposites is a new and emerging area,
and worthy of further investigation, due to the virus-like surface
of dot-coated LDH nanocomposites and the availability for
multi-functionalisation.
Fig. 14 (a) Schematic illustration of the synthetic process and proposed
structures of functional LDH@SiO2 nanocomposites. (b–d) TEM images of
LDH (b), LDH@SiO2 (c), and LDH@SiO2–NH2 (d), and the scale bars of the
inset are 100 nm. (e–g) Particle size distribution of LDH (e), LDH@SiO2 (f),
and LDH@SiO2–NH2 (g). Reproduced from ref. 111 with permission.
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Although there have been rapid advances in the synthesis
and application studies of LDH-based nanocomposites, it is
still a newly emerging area and there is a great deal of room for
researchers to explore in this area. Constructing a new hierar-
chical structure will not only provide a new conceptual struc-
ture and synthesis approach, but will also offer an opportunity
for potential applications. When an LDH-based nanocomposite
is designed and synthesised, it is a priority question to consider
whether the nanocomposite takes full use of LDH and other
nanomaterials. By fabricating LDHs with different metal
cations and anions, LDH could be a candidate to be used for
different modes of bio-imaging as contrast agents, production
of a number of compounds as catalysts, and delivery of various
therapeutic molecules.
Towards the final goal of transferring LDH-based nano-
composites from bench to industry, there are several challenges
to address. One of the major challenges is to simplify the
synthesis process with precise control of particle size and
morphology. This is also the prerequisite for scale-up. For
LDH-based nanocomposites to be used in clinics, the colloidal
stability of the nanocomposites also needs to be considered, as
the aggregated particles would lower the therapeutic efficacy or
even block the blood vessel to cause the clot eventually. The
lack of bio-safety and the bio-distribution profile for healthcare
application is another challenge. Future research should focus
on closely linking up the nanocomposite physicochemical
properties with practical applications, including, but not
limited to, therapeutics, diagnosis, water and air purification,
energy storage, and energy conversion.
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